Business ❯ Finance ❯ Investments ❯ Mergers and Acquisitions

Pharmaceutical Acquisitions

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

GSK moves to fortify its immunology pipeline with a mid‑stage anti‑IgE drug that could shift food‑allergy care.

Merck Reportedly Weighs $28–$32 Billion Deal for Revolution Medicines After AbbVie Denial

Eli Lilly to Acquire Ventyx Biosciences for $1.2 Billion in Bet on Oral NLRP3 Drugs

Sanofi to Buy Dynavax for $2.2 Billion in All-Cash Tender Offer

Samsung Biologics to Buy GSK’s Human Genome Sciences Campus for $280 Million

Lilly to Buy Adverum in Gene‑Therapy Deal Worth Up to $12.47 a Share

Pfizer to Buy Metsera for $4.9 Billion Upfront in Return to Obesity Drugs

Merck to Acquire Verona Pharma in $10 Billion Deal for Ohtuvayre COPD Therapy

Sanofi to Acquire Blueprint Medicines for $9.1 Billion, Boosting Its Rare Immunology Pipeline